Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: ravulizumab | Statement: [Alexion Pharmaceuticals, keyDrug, ravulizumab]

Target entity: ravulizumab
Context triple: [Alexion Pharmaceuticals, keyDrug, ravulizumab]

• A. idarucizumab
  Idarucizumab is a monoclonal antibody fragment used as a specific antidote to rapidly reverse the anticoagulant effects of dabigatran in cases of emergency or uncontrolled bleeding.
• B. ocrelizumab
  Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
• C. Ofatumumab
  Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
• D. Taltz
  Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
• E. Actemra
  Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: ravulizumab
Triple: [Alexion Pharmaceuticals, keyDrug, ravulizumab]

Ravulizumab is a long-acting monoclonal antibody complement inhibitor used to treat rare blood disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Target entity: ravulizumab
Target entity description: Ravulizumab is a long-acting monoclonal antibody complement inhibitor used to treat rare blood disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

• A. idarucizumab
  Idarucizumab is a monoclonal antibody fragment used as a specific antidote to rapidly reverse the anticoagulant effects of dabigatran in cases of emergency or uncontrolled bleeding.
• B. ocrelizumab
  Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
• C. Ofatumumab
  Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
• D. Taltz
  Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
• E. Actemra
  Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
• F. None of above. chosen